Acquisition of TheraClear Assets (Tables)

3 Months Ended

Mar. 31, 2022

Acquisition of TheraClear Assets [Abstract]

Purchase Price Allocation

The purchase price was allocated, on a relative fair basis, to the technology intangible asset and acquired inventories as follows:

Consideration:
Cash payment	$	500
Common stock issued		500
Transaction costs		131
Contingent consideration		9,122
Total consideration	$	10,253
Assets acquired:
Technology intangible asset	$	10,182
Inventories		71
Total assets acquired	$	10,253